A5025122447- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- Cancer-related Molecular Pathways
- Multiple Myeloma Research and Treatments
- Diabetes and associated disorders
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- Vitamin D Research Studies
- Chronic Myeloid Leukemia Treatments
- T-cell and B-cell Immunology
- Lung Cancer Treatments and Mutations
- Cancer Mechanisms and Therapy
- Immunotherapy and Immune Responses
- Cutaneous lymphoproliferative disorders research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Glycosylation and Glycoproteins Research
- Angiogenesis and VEGF in Cancer
- Protease and Inhibitor Mechanisms
- Cancer Treatment and Pharmacology
- Influenza Virus Research Studies
Wroclaw Medical University
2015-2025
University of Wrocław
2008-2025
Niepubliczna Wyższa Szkoła Medyczna
1993-2006
Medical University of Lublin
2004
Institut pour la Recherche sur le Cancer de Lille
2001
Inserm
2001
New York Academy of Medicine
1996
Hôpital Edouard Herriot
1988-1996
Université Claude Bernard Lyon 1
1993-1995
In the present study, we have examined kinetics and magnitude of expression CD28 CD152 molecules on unstimulated anti-CD3+rIL-2-stimulated peripheral blood CD4+ CD8+ T cells in patients with chronic lymphocytic leukaemia (B-CLL) controls. The mean percentages both CD3+/CD4+/CD28+ CD3+/CD8+/CD28+ were significantly lower B-CLL than controls before culture, decreased rapidly, reaching their lowest levels between 24 48 h, returned to basal after 72 h culture. controls, proportions found...
Background. The extrathyroid, orbital manifestation of Graves' disease (GD)—Graves' orbitopathy (GO)—presents a difficult clinical problem. immunological status GO patients is still under investigation. aim this study was to assess the serum concentration interleukin 6 (IL-6), soluble receptor (sIL-6R), and CD8+CD28− lymphocytes in evaluate if these parameters were associated with activity. Patients. Thirty-nine (29 women 10 men, aged 24–71, mean 50.18) newly diagnosed GD enrolled study....
The aim of this study was to analyze the association between gene polymorphisms killer‐cell immunoglobulin‐like receptors ( KIRs ) and their human leukocyte antigen HLA ligands susceptibility B‐cell chronic lymphocytic leukemia (B‐CLL) clinical course disease. distribution individual KIR genes in 197 B‐CLL patients 200 controls similar, except for a tendency lower frequencies KIR2DS3 KIR2DL5 among (26.9% vs 35.5%, P = 0.06, 46.2% 55.5%, 0.06). associations reached statistical significance...
Recently, systemic administration of a human monoclonal antibody directed against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on circulating cells in patients with chronic lymphocytic leukaemia (CLL) has been considered. Also, CLL have shown to express CTLA-4, increased levels which the leukaemic compartment are predictor good clinical outcome. Since both and Treg microenvironment can be targeted by CTLA-4 blocking this immunotherapy approach, investigation functional...
Chronic lymphocytic leukemia (CLL) is characterized by the peripheral accumulation of neoplastic B cells and frequently complicated systemic immunosuppression associated with an impairment in T lymphocyte activation. We hypothesized that expression immune checkpoint suppressors attenuator (BTLA) cytotoxic antigen (CTLA-4) disturbed both subpopulations CLL. The CTLA-4 BTLA mRNA was determined real-time PCR, while protein (surface or intracellular) estimated BTLA+ lymphocytes flow cytometry....
A unique feature of chronic lymphocytic leukemia (CLL) is the increased number circulating T cells preventing malignant B from undergoing apoptosis. Dysregulated expression p27Kip1 and cyclin D2 (G1 phase regulators controlling lymphocyte survival) was examined in leukemic but not non-malignant cells. Assessment anti-apoptotic peripheral blood (PB) relation to ex vivo apoptosis CLL patients with different clinical courses. Using flow cytometry, we determined G1 regulators' 47 previously...
Introduction: Primary renal lymphoma is extremely rare, accounting for less than 1% of all lymphomas. Objectives: The aim this study was to describe a group patients with primary diagnosed in hematology and oncology centers aligned the Polish Lymphoma Research Group (PLRG). Patients methods: This retrospective analysis adult at PLRG centers. Results: Thirty-two were seven over 24 years (2000–2023). most common type diffuse large B-cell (DLBCL). median progression-free survival (PFS) after...
Venetoclax (VEN) and cladribine (2-CdA) are active agents in the treatment of chronic lymphocytic leukemia (CLL), although their precise pro-apoptotic mechanisms CLL cells remain unclear. However, vitro studies suggest that these drugs may alter expression several proteins involved apoptosis. The aim study was to evaluate effect VEN 2-CdA, used individually combination, on apoptosis-related genes vitro. Mononuclear were collected from peripheral blood 40 previously untreated patients. 17...
The number of newly diagnosed haematological malignancies in Polish adults and children is about 9,000 a year, which constitutes 5.5% all the country. Adult patients with are treated 42 institutions Poland. scientific educational support for this activity provided under umbrella Society Haematologists Transfusiologists (PTHiT, Polskie Towarzystwo Hematologów i Transfuzjologów ), Leukemia Group (PALG), Lymphoma Research (PLRG), Myeloma Study (PMSG), Consortium (PMC), consultants haematology....
Introduction: Activity of metalloproteinases (MMP) is controlled both by specific tissue inhibitors (TIMP) and activators (extracellular matrix metalloproteinase inducer, EMMPRIN). There are few data available concerning concentration the bone marrow MMP-2, MMP-9, TIMP-1, TIMP-2, or EMMPRIM expression mesenchymal stromal cells (BMSCs) in patients with multiple myeloma (MM).
Germline mutations of the CHEK2 gene have been reported in some myeloid and lymphoid malignancies, but their impact on development essential thrombocythemia has not studied. In 16 out 106 (15.1%) consecutive patients, newly diagnosed with thrombocythemia, we found one four analyzed mutations: I157T, 1100delC, IVS2+1G>A or del5395. They were associated increased risk disease (OR=3.8; P=0.002). The median age at ET diagnosis among CHEK2+/JAK2V617F+ patients was seven years lower than that...
Background. Graves' orbitopathy (GO), also known as thyroid-associated ophthalmopathy, is characterized by dramatic tissue reactivity. Both inflammation and remodeling characterize the clinical course of GO. Some data has been found regarding association MMPs TIMPs in GO.Material Methods. Serum concentrations MMP-9, MMP-2, TIMP-1, TIMP-2 were determined ELISA method.Objectives. Forty-eight patients (34 females, 14 males, with median age 51.5 years) GD hyperthyroidism enrolled study. In 28...
PIM-2 is a proto-oncogene that encodes for serine/threonine kinase interacts with various signaling molecules. highly expressed in neoplastic tissues and leukemic lymphoma cell lines, which consistent its role during oncogenic transformation. The nuclear factor kappa B (NF-κB) pathway appears to be deregulated variety of tumors, sustained activity NF-κB leading apoptotic resistance tumor cells. aim this study was investigate whether expression altered acute myeloid leukemia (AML)...
The B-cell activator factor (BAFF)/BAFF receptor (BAFF-R) axis seems to play an important role in the development and progression of chronic lymphocytic leukemia (CLL). Here, we investigated association eight single nucleotide polymorphisms (SNPs) BAFF (TNFSF13B) BAFF-R (TNFRSF13C) genes with risk sporadic CLL a group 439 patients 477 controls. We also examined correlation between selected SNPs clinical parameters as well plasma levels intracellular expression. Our results point possible...
Przewlekła białaczka limfocytowa (PBL) jest chorobą osób starszych z medianą wieku przy rozpoznaniu około 70 lat. Naturalny przebieg choroby bardzo zróżnicowany, a chorzy bezobjawową i nieprogresywną postacią białaczki nie wymagają terapii. Wskazaniem do leczenia pozostaje zaawansowana progresywna PBL. Wyniki PBL uległy istotnej poprawie dzięki wprowadzeniu nowych, skutecznych leków: inhibitorów receotora limfocyta B (BCR) oraz BCL2 (B Cell lymphoma 2). Leki te w monoterapii stosuje się...